Cara Therapeutics Inc

For the period ended Dec 31, 2023. Filed Mar 6, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 6, 2024

TVRD$1.41+47.2%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Comprehensive Loss


· · Year Ended December 31,
	2023		2022		2021
Revenue:
Collaborative revenue		$12,936		$16,572		$706
Commercial supply revenue		5,843		10,223		701
License and milestone fees		910		15,000		21,223
Royalty revenue		415		72		—
Clinical compound revenue		165		—		398
Other revenue		699		—		—
Total revenue		20,968		41,867		23,028
Operating expenses:
Cost of goods sold		6,174		7,266		—
Research and development		108,510		91,879		82,701
General and administrative		27,779		30,257		29,410
Total operating expenses		142,463		129,402		112,111
Operating loss		(121,495)		(87,535)		(89,083)
Other income, net		3,586		2,061		642
Non-cash interest expense on liability related to sales of future royalties and milestones		(604)		—		—
Net loss		$(118,513)		$(85,474)		$(88,441)
Net loss per share:
Basic and Diluted		$(2.19)		$(1.59)		$(1.74)
Weighted average shares:
Basic and Diluted		54,149,059		53,653,564		50,718,765
Other comprehensive income (loss), net of tax of $0:
Change in unrealized gains (losses) on available-for-sale marketable securities		1,412		(1,314)		(431)
Total comprehensive loss		$(117,101)		$(86,788)		$(88,872)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.